ETNB Stock Cash Flow Statements

89bio Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

89bio Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31

cash flows from operating activities:
net income	-111,504,000	-71,275,000	-118,354,000	-149,073,000	-47,971,000	-51,681,000	-40,235,000	-34,725,000	-38,393,000	-28,836,000	-24,602,000	-26,805,000	-25,054,000	-25,565,000	-26,288,000	-28,329,000	-20,723,000	-14,782,000	-12,581,000	-14,603,000	-11,771,000	-10,544,000
adjustments to reconcile net income to net cash from operating activities:
stock-based compensation	7,315,000	7,216,000	5,205,000	5,262,000	5,169,000	4,998,000	4,037,000	4,381,000	4,137,000	3,551,000	2,758,000	2,500,000	2,586,000	2,512,000	2,154,000	2,314,000	2,417,000	1,793,000
net accretion of discounts on investments in marketable securities	-2,326,000	-1,898,000		-2,481,000	-2,584,000	-2,822,000
amortization of debt discount and accretion of deferred debt costs	318,000	455,000	326,000	175,000	168,000	162,000
noncash operating lease expense	153,000	163,000	188,000	182,000	176,000	175,000		42,000	42,000	41,000
depreciation	8,000	10,000	9,000	8,000	12,000	9,000	16,000	10,000	10,000	14,000	15,000	16,000	16,000	18,000	21,000	23,000	20,000	15,000	13,000	18,000	17,000	12,000
change in fair value of warrant liability	-295,000	-221,000
other
changes in operating assets and liabilities:
prepaid expenses and other assets	3,667,000	-7,869,000
accounts payable	-152,000	-600,000	-3,963,000	2,019,000	2,235,000	6,767,000	-2,318,000	188,000	-6,012,000	4,225,000	-1,649,000	9,244,000	486,000	-2,422,000	-5,681,000	10,618,000	-2,609,000	2,450,000	-1,673,000	681,000	-943,000	3,066,000
accrued expenses	1,827,000	2,323,000	1,122,000	235,000	-1,867,000	457,000	5,687,000	-923,000	7,939,000	-4,827,000	-1,493,000	-951,000	5,409,000	-1,215,000	2,875,000	1,654,000	1,727,000	-2,110,000	969,000	1,648,000	-301,000	-888,000
operating lease liabilities	-176,000	-178,000	-207,000	-198,000	-120,000	29,000
other noncurrent liabilities	740,000	137,000	677,000	2,000	-87,000	97,000
net cash from operating activities	-100,425,000	-71,737,000	-121,580,000	-145,359,000	-61,164,000	-39,720,000	-34,293,000	-30,361,000	-34,447,000	-30,085,000	-27,096,000	-14,815,000	-14,835,000	-24,344,000	-28,240,000	-13,450,000	-20,109,000	-14,982,000	-14,028,000	-12,940,000	-11,524,000	-7,752,000
capex	0	-72,000	0	0	0	0	0	0	0	0	-2,000	0	1,000	-6,000	-27,000	-16,000	-16,000	-4,000	-2,000	-17,000	-46,000	-61,000
free cash flows	-100,425,000	-71,809,000	-121,580,000	-145,359,000	-61,164,000	-39,720,000	-34,293,000	-30,361,000	-34,447,000	-30,085,000	-27,098,000	-14,815,000	-14,834,000	-24,350,000	-28,267,000	-13,466,000	-20,125,000	-14,986,000	-14,030,000	-12,957,000	-11,570,000	-7,813,000
cash flows from investing activities:
proceeds from sales and maturities of marketable securities	114,790,000	97,341,000	82,850,000	74,285,000	105,950,000	72,140,000
purchases of marketable securities	-221,412,000	-105,102,000	-63,011,000	-82,924,000	-78,101,000	-152,038,000
purchases of property and equipment	0	-72,000									-2,000	0	1,000	-6,000	-27,000	-16,000	-16,000	-4,000	-2,000	-17,000	-46,000	-61,000
net cash from investing activities	-106,622,000	-7,833,000	19,824,000	-8,639,000	27,849,000	-79,898,000	-63,643,000	38,326,000	-101,808,000	4,106,000	-11,061,000	-42,058,000	-7,596,000	26,772,000	19,086,000	17,359,000	-13,876,000	-15,410,000	-29,028,000	-71,999,000	-5,744,000	-61,000
cash flows from financing activities:
proceeds from issuance of common stock and pre-funded warrants in public offering, net of issuance costs	0	269,903,000
payments of deferred offering costs			-137,000	0	137,000	-253,000
proceeds from issuance of common stock under at-the-market program, net of issuance costs
proceeds from issuance of common stock upon exercise of common stock warrants			0	24,664,000	27,745,000	1,798,000
proceeds from issuance of common stock upon exercise of stock options	26,000	33,000	99,000	82,000	-43,000	104,000	4,000	117,000	327,000	185,000	68,000											9,000
proceeds from issuance of common stock under employee stock purchase plan			178,000	0
payments for taxes related to net share settlement upon vesting of restricted stock units	-568,000	-1,030,000	-18,000	-904,000	-39,000	-1,686,000
net cash from financing activities	20,727,000	268,906,000	136,405,000	33,191,000	27,960,000	21,030,000	162,171,000	-1,480,000	30,766,000	321,654,000	21,011,000	68,631,000	28,160,000	29,000	21,891,000	72,000	1,692,000	216,000	-312,000	158,292,000	-65,000	9,000
net change in cash and cash equivalents	-186,320,000	189,336,000	34,649,000	-120,807,000	-5,355,000	-98,588,000
cash and cash equivalents at beginning of period	0	126,060,000		0	0	316,161,000
cash and cash equivalents at end of period	-186,320,000	315,396,000		-120,807,000	-5,355,000	217,573,000
supplemental disclosures of cash information:
cash paid for interest	827,000	814,000	1,082,000	685,000	689,000	679,000	680,000	715,000	656,000	542,000	370,000	302,000	235,000	169,000
proceeds from issuance of common stock in at-the-market public offering, net of issuance costs							0	0	23,667,000	13,422,000	20,083,000
accretion of discounts on marketable securities, net of amortization of premiums
loss on extinguishment of debt			0
prepaid and other assets			-4,527,000	-2,880,000	-16,408,000	2,089,000
proceeds from issuance of common stock and warrants in public offerings, net of issuance costs
proceeds from issuance of common stock in at-the-market public offerings, net of issuance costs			0	0	-18,000	21,067,000
proceeds from term loan facility, net of issuance costs			0				0	0	0	24,363,000					18,500,000	-6,000
repayment of term loan
cash and cash equivalents:
beginning of period
end of period
cash paid for amounts included in the measurement of lease liabilities			268,000	267,000
supplemental disclosures of noncash information:
unpaid offering costs included in accrued expenses						18,000
right-of-use assets obtained in exchange for operating lease liabilities
remeasurement of lease liability and right of use asset in connection with lease modification											0
issuance of common stock warrants in connection with term loans
proceeds from issuance of common stock in public offerings, net of issuance costs
issuance of common stock warrants in connection with term loan								0	0	482,000
cash paid related to operating lease liabilities						46,000
net amortization of investments in marketable securities
non-cash operating lease expense											40,000	44,000
deferred tax assets
other non-current liabilities
proceeds from issuance of common stock upon espp purchases							126,000	0			7,000	0
net change in cash and cash equivalents, and restricted cash							64,235,000	6,485,000	-105,489,000	295,675,000	-17,146,000	11,758,000	5,729,000	2,457,000	12,737,000
cash and cash equivalents, and restricted cash at beginning of period							0	0	0	55,255,000	0	0	0	52,457,000	0	0	0	98,208,000	0	0	0	93,360,000
cash and cash equivalents, and restricted cash at end of period									-105,489,000	350,930,000	-17,146,000	11,758,000	5,729,000	54,914,000	12,737,000	3,981,000	-32,293,000	68,032,000	-43,368,000	73,353,000	-17,333,000	85,556,000
components of cash and cash equivalents, and restricted cash:
cash and cash equivalents									-105,489,000	350,930,000	-17,146,000	11,783,000	5,729,000	54,889,000	12,737,000	3,981,000	-32,293,000	68,007,000	-43,368,000	73,352,000	-17,333,000	85,532,000
restricted cash													0	25,000	0	0	0	25,000	0	1,000	0	24,000
total cash and cash equivalents, and restricted cash									-105,489,000	350,930,000	-17,146,000	11,758,000	5,729,000	54,914,000	12,737,000	3,981,000	-32,293,000	68,032,000	-43,368,000	73,353,000	-17,333,000	85,556,000
right-of-use assets obtained in exchange for new operating lease liabilities
issuance of common stock warrant in connection with term loan facility															0	0			0	0
net accretion on available-for-sale securities
accretion of final payment fee on term loan								100,000	98,000	87,000		120,000
amortization of debt issuance costs								139,000	139,000	132,000		75,000	77,000	75,000		198,000	117,000	77,000	76,000	77,000
loss on extinguishment of term loan facility								0	0	1,208,000
prepaid and other current assets								2,578,000	-1,217,000	-4,599,000	-1,425,000	719,000	2,095,000	1,942,000	-1,553,000	-87,000	-1,306,000	-2,726,000
other assets												579,000	-579,000	72,000		-73,000	5,000	72,000
operating lease liability								-42,000	-42,000	-41,000	-43,000	-45,000
proceeds from sales and maturities of available-for-sale securities								74,548,000	45,000,000	37,880,000					40,795,000	43,675,000
purchases of available-for-sale securities								-36,222,000	-146,808,000	-33,774,000	-42,559,000	-69,406,000	-31,330,000	-9,401,000	-21,682,000	-26,300,000	-47,916,000	-45,302,000	-40,190,000	-73,007,000
proceeds from issuance of common stock in public offering, net of issuance costs								0	0	296,817,000
proceeds from issuance of common stock upon exercise of warrants								0	6,630,000	8,960,000	1,029,000
payment of withholding taxes related to restricted stock units								-1,597,000	0	-693,000	-176,000	-53,000
repayment of term loan facility								0	0	-21,400,000
cash paid for operating leases								46,000	46,000	47,000	47,000	60,000
net amortization on available-for-sale securities									-1,148,000	-1,040,000
offering costs included in other assets and accrued expenses
amortization of debt issuance costs and accretion of final payment fee
proceeds from issuance of common stock and warrants in public offering, net of issuance costs											0
amortization of premium on available-for-sale securities												-311,000	10,000	118,000	161,000	232,000	243,000	229,000	183,000	84,000
proceeds from maturities of available-for-sale securities												27,348,000	23,733,000	36,179,000				29,896,000	11,164,000
supplemental disclosures of non-cash information:
proceeds from public offering, prior to closing
proceeds from issuance of common stock upon stock option exercises													0	29,000	41,000	78,000	152,000	216,000	236,000	5,000
purchases of property and equipment included in accounts payable and accrued expenses
debt issuance costs included in accounts payable
accretion of final payment fee														121,000
cash paid for income taxes
proceeds from issuance of common stock upon public offerings, net of issuance costs
payment of debt issuance costs																			0	0
proceeds from issuance of common stock upon espp purchase																0				0
supplemental cash flow disclosures:
offering costs included in accounts payable and accrued expenses
net decrease in cash and cash equivalents, and restricted cash																	-32,293,000	-30,176,000				-7,804,000
property and equipment purchases included in accounts payable and accrued expenses																	-3,000	6,000				54,000
deferred offering costs included in accrued expenses
cash paid for taxes																		154,000	7,000
share-based compensation																			1,250,000	1,154,000	910,000	493,000
revaluation of convertible preferred stock liability
prepaids and other current assets																					486,000	109,000
proceeds from issuance of common stock upon initial public offering, net of issuance costs
proceeds from issuance of convertible preferred stock and convertible preferred stock liability, net of issuance costs
proceeds from issuance of common stock
net increase in cash and cash equivalents, and restricted cash																			-43,368,000	73,353,000
property and equipment purchases included in accounts payable
conversion of convertible preferred stock into common stock at close of initial public offering
capital contribution related to extinguishment of convertible preferred stock liability
proceeds from issuance of common stock upon public offering, net of issuance costs
proceeds from issuance of convertible preferred stock and convertible preferred stock liability, net of issuance cost
payment of deferred offering costs
deferred offering costs included in accounts payable and accrued expenses
supplemental disclosures of non-cash investing and financing activities:
noncash investing and financing activities:
proceeds from issuance of convertible note
proceeds from initial public offering net of issuance costs
cash and cash equivalents, and restricted cash at beginning of year
cash and cash equivalents, and restricted cash at end of year
conversion of convertible note into preferred stock
capital contribution related to extinguishment of preferred stock liability

We provide you with 20 years of cash flow statements for 89bio stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of 89bio stock. Explore the full financial landscape of 89bio stock with our expertly curated income statements.

The information provided in this report about 89bio stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.